ClinicalTrials.gg
CompletedNCT07499908CityskyUpdated Oct 21, 2026

Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013

A Phase 1 interventional study of CIT-013 high dose and Placebo in Healthy Adult, sponsored by Citryll BV. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Citryll BV · Phase 1, Interventional, and Treatment

Updated Oct 21, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers

Read the detailed description

The active treatment in this trial is CIT-013, an investigational medicinal product that will be administered at a fixed dose level of 150 mg, subcutaneous (one 50 mg and one 100 mg injection), and is compared against placebo. CIT-013 is an IgG1k monoclonal antibody consisting of two identical light chain polypeptides composed of 219 amino acids each and two identical heavy chain polypeptides composed of 451 amino acids each. CIT-013 and placebo will be administered via subcutaneous injection in the abdominal wall.

02

Conditions studied

  • Healthy Adult
03

In context

Lead sponsor

Citryll BV is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men or women, 18 to 75 years of age (inclusive) at screening.
  • Informd Consent
  • is between 18.0 and 32.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the trial, or that would pose an unacceptable risk to the participant in the opinion of the Investigator.
  • Any history of severe allergic reaction(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    CIT-013 high dose

    CIT-013 high dose

    Drug: CIT-013 high dose

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Frequency and severity of treatment-emergent adverse events (TEAE) throughout the trial period, including clinically relevant findings, and antidrug antibody (ADA) results.

    Time frame: 6 weeks

07

Study locations

1 site
  • ICON
    Groningen, Netherlands
08

References and documents

Publications

  • https://doi.org/10.1080/19420862.2023.2281763

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Aug 2026, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start May 2026 → Jun 2026 and completion Oct 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartActual
Jun 23, 2026was May 2026
Primary completionActual
Aug 10, 2026
CompletionActual
Aug 12, 2026was Oct 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 21, 2026
Start date
May 31, 2026→Jun 23, 2026 (actual)
Oct 21, 2026
Primary completion
Aug 15, 2026→Aug 10, 2026 (actual)
Oct 21, 2026
Study completion
Oct 31, 2026→Aug 12, 2026 (actual)
Oct 21, 2026
Eligibility
2 inclusion criteria added; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedInformd Consent
  • AddedBody mass index is between 18.0 and 32.0 kg/m2
Exclusion criteria
  • AddedAny history of severe allergic reaction(s)
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Safety and tolerabilityNow Incidence of Treatment-Emergent Adverse EventsTime frame: 6 weeks
Oct 21, 2026
Title
Phase 1 TrialTrial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Completed
    Start date May 31, 2026→Jun 23, 2026 (now actual)
    Primary completion Aug 15, 2026→Aug 10, 2026 (now actual)
    Study completion Oct 31, 2026→Aug 12, 2026 (now actual)
    Eligibility 2 inclusion criteria added; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedInformd Consent
    • AddedBody mass index is between 18.0 and 32.0 kg/m2
    Exclusion criteria
    • AddedAny history of severe allergic reaction(s)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Safety and tolerabilityNow Incidence of Treatment-Emergent Adverse EventsTime frame: 6 weeks
    Title Phase 1 TrialTrial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07499908
Lead sponsor
Citryll BV
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Jun 23, 2026
Primary completion
Aug 10, 2026
Completion
Aug 12, 2026
Last update
Oct 21, 2026

Study contacts

Maarten Kraan
study director · Citryll BV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CIT-013

Start the discussion